<SEC-DOCUMENT>0000950170-25-081674.txt : 20250604
<SEC-HEADER>0000950170-25-081674.hdr.sgml : 20250604
<ACCEPTANCE-DATETIME>20250604163744
ACCESSION NUMBER:		0000950170-25-081674
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20250603
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250604
DATE AS OF CHANGE:		20250604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGENUS INC
		CENTRAL INDEX KEY:			0001098972
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				061562417
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29089
		FILM NUMBER:		251023659

	BUSINESS ADDRESS:	
		STREET 1:		3 FORBES ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-674-4410

	MAIL ADDRESS:	
		STREET 1:		3 FORBES ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTIGENICS INC /DE/
		DATE OF NAME CHANGE:	19991115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>agen-20250603.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-06-04T16:35:27.8045+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:agen="http://www.agenusbio.com/20250603" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e5edd971-83ab-4d37-89ff-dc7bb740703b" name="dei:EntityCentralIndexKey" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8">0001098972</ix:nonNumeric><ix:nonNumeric id="F_a667d0ef-b20b-4a5e-9c17-f0e652e6c566" name="dei:AmendmentFlag" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="agen-20250603.xsd"/></ix:references><ix:resources><xbrli:context id="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001098972</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-03</xbrli:startDate><xbrli:endDate>2025-06-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1174f8c9-889e-43e9-b0eb-6c58db1c99e3" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_a52b9fe7-7637-4719-8eec-ba954e82bac4" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 03, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c025f7ba-9d03-42ec-8312-5e2c8e6d8d24" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGENUS INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2a65ade1-48ef-4335-906f-74de893392a8" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1a50f991-0774-4c01-984c-5693ca5e7c08" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">000-29089</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ac175431-5d01-45f1-bfb6-327ba65f77f5" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">06-1562417</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_38fff53e-742a-4b97-8396-40f4365f5661" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3 Forbes Road</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_843b8184-2c71-4985-851f-1c758ae7a0eb" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lexington</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_21ee9edc-2d9c-4744-8ff9-15f65ddfa5e8" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c67094a7-d5c3-40bc-94f9-733c2c5ac3c7" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02421</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_7480dae3-a386-4bc0-9675-72236e702449" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">781</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_a1748922-0d7f-4c2b-ba9e-89c3e083d923" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">674-4400</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_261ee0de-ca40-4458-8ee2-3683a48a4b77" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d65e28c2-b337-4339-b3d4-e733b2259292" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa78a67b-c4fc-40ad-8657-8c8f3f7fe8e4" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_440c0d61-d3e1-4a18-9067-3bf89a55fb85" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d0cd289a-6459-4b65-92ca-40cee4f6c120" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.01 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f6fccacc-c20e-47e5-9333-2d044f384aa6" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AGEN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_35aa30b9-6d1f-46e5-95bc-fe563123b61a" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_6e47dc6d-9b19-4636-a3ca-213eade60afd" contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1.01 Entry into a Material Definitive Agreement.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Purchase Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 3, 2025, Agenus Inc. (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) and its wholly-owned subsidiary Agenus West, LLC (&#8220;Agenus West&#8221; and together with the Company, &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agenus</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) entered into an Asset Purchase Agreement (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) with Zydus Pharmaceuticals (USA) Inc. (&#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zydus</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;), a wholly owned subsidiary of Zydus Lifesciences Limited, for the sale to Zydus of substantially all of the assets comprising Agenus&#8217; manufacturing operations run primarily through Agenus West (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchased Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;), including without limitation real estate, equipment and certain assumed contracts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the sale of the Purchased Assets, Zydus will pay Agenus up to $125 million, comprised of $75 million to be paid at closing (minus any amounts used by Zydus to satisfy related indebtedness at closing) and contingent payments of up to an additional $50 million that may be earned based on usage by Agenus of Zydus&#8217; manufacturing business during the 36-month period following the closing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Purchase Agreement contains customary representations, warranties and agreements by Agenus and Zydus, indemnification obligations of the parties and certain other obligations of the parties.  Closing of the transaction is subject to customary conditions, including receipt of all required government approvals, as well as the entry into a contract manufacturing agreement (under which Agenus will use Zydus for agreed manufacturing needs), the SPA (as defined below) and a license agreement (under which Zydus would receive an exclusive license to develop, manufacture and commercialize botensilimab and balstilimab (&#8220;BOT/BAL&#8221;) in India and Sri Lanka (the &#8220;Territory&#8221;) in exchange for a royalty on net sales in the Territory) (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 3, 2025 and in connection with the execution of the Purchase Agreement, the Company and Zynext Ventures USA LLC (&#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zynext</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;), a wholly-owned subsidiary of ZyNext Ventures PTE.LTD Singapore, a wholly-owned subsidiary  of Zydus Lifesciences Limited, entered into a Securities Purchase Agreement (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and together with the License Agreement and Purchase Agreement the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zydus Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;), pursuant to which Zynext agreed to purchase 2,133,333 shares of the Company&#8217;s common stock (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) for an aggregate purchase price of approximately $16.0 million, or $7.50 per share. Under the SPA, Zynext has agreed not to dispose of any of the Shares for a period of 12 months and to refrain from acquiring additional shares of Common Stock for a period of 12 months, other than in specified circumstances. The Company has agreed to register the Shares for resale under the Securities Act of 1933, as amended (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;). The Company has also agreed to allow Zynext to designate a non-voting board observer or, in lieu of delegating a board observer, to nominate one director for election to the Company&#8217;s Board of Directors, subject to Zynext or its affiliates maintaining certain ownership in the Company. Subject to certain restrictions, customary information rights and preemptive rights will be granted to Zynext under the SPA for so long as Zynext maintains certain ownership of Company&#8217;s outstanding Common Stock. Closing under the SPA is subject to customary closing conditions, including receipt of all required government approvals and satisfaction or waiver of the conditions precedent to closing contained in the Asset Purchase Agreement. The SPA also includes customary representations and warranties, covenants and indemnification obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the License Agreement, the Company grants Zydus Lifesciences Limited an exclusive license in the Territory under its patents and know-how to develop, manufacture, and commercialize products based on its proprietary BOT/BAL cancer immunotherapy drug product.  As consideration for this license Zydus agrees to pay Agenus a royalty on net sales at a rate of 5%, as may be adjusted by the occurrence of certain contingencies, for a period ending at the later of the expiration of Agenus&#8217; patent rights in a given country in the Territory or 10 years following first commercial sale in such country.  The parties further agree in the License Agreement to use reasonable efforts to enter into supply agreements under which Agenus would supply BOT/BAL to Zydus for clinical trials and commercialization.  Zydus agrees to be responsible for conducting clinical trials and seeking regulatory approval in the Territory as set forth in the License Agreement.  The License Agreement contains customary representations and warranties by Agenus and Zydus, confidentiality and indemnification obligations of the parties, customary termination conditions, and certain other obligations of the parties customary for these types of license agreements.  Effectiveness of the License Agreement is subject to conditions to effectiveness, including satisfaction or waiver of the conditions precedent to closing contained in the Purchase Agreement and the SPA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Zydus Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the Zydus Agreements, copies of which will be filed as exhibits to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 3, 2025, the Company issued a press release announcing its entry into the Zydus Agreements, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 to this Current Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99.1	</span><a href="agen-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Press release dated June 3, 2025</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 4, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Garo H. Armen, Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Garo H. Armen, Ph.D.<br/>Chairman and CEO</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>agen-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><img src="img250783414_0.jpg" alt="img250783414_0.jpg" style="width:152px;height:31px;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">FOR IMMEDIATE RELEASE</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus&#x2019; Biologics Manufacturing in the US</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$75M upfront payment to Agenus for the transfer of manufacturing assets </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$50M of contingent payments to Agenus </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exclusive license for BOT/BAL in India and Sri Lanka </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$16M equity investment at $7.50 per share</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">LEXINGTON, Mass&#x2013; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">June 3, 2025 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agenus Inc</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Nasdaq: AGEN</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as &#x201c;Zydus,&#x201d; designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The strategic collaboration includes an exchange of Agenus&#x2019; state-of-the-art biologics CMC facilities in Emeryville, CA and Berkeley, CA for upfront consideration of $75M; Agenus to receive up to an additional $50M in contingent payments triggered by BOT/BAL production orders. Zydus, an India-based multinational pharmaceutical company with over 27,000 employees and operations in 55 countries, will launch a BioCDMO business using the facilities as their flagship U.S. sites to provide biologics contract manufacturing services to biopharmaceutical companies globally.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agenus will become Zydus&#x2019; first BioCDMO customer through an exclusive manufacturing agreement for BOT/BAL to ensure the combination regimen&#x2019;s BLA and launch readiness needs. This collaboration enables Agenus to unlock the value of its manufacturing assets and secure strategic capital to drive BOT/BAL toward global regulatory engagement and commercialization.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agenus will also grant Zydus an exclusive license to develop and commercialize BOT and BAL in India and Sri Lanka, capitalizing on Zydus&#x2019; established local market presence and infrastructure. Zydus will pay Agenus a 5 percent royalty on net sales in those countries.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In a demonstration of mutual commitment, Zydus will also make a strategic equity investment in Agenus by purchasing approximately 2.1 million shares of common stock at $7.50 per share, totaling approximately $16 million in gross proceeds. Agenus intends to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">apply the net proceeds from the sale of the purchased shares for working capital and general corporate purposes, and will accelerate ongoing clinical development, registration and potential commercialization of BOT/BAL.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">By uniting Agenus&#x2019; pioneering research and development capabilities with Zydus&#x2019; worldwide manufacturing, commercialization and operational strength, this partnership sets the stage for a new era in cancer immunotherapy in India and beyond.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;With a trade agreement between the United States and India seemingly imminent, there is a renewed sense of confidence by trading partners in both countries in the future of Indian-American relations,&#x201d; said Dr. Garo Armen, CEO of Agenus. &#x201c;There is also a growing recognition by both countries of the need for the United States to ensure that biopharma supply chains are secure. We are working with Zydus to accelerate future clinical trials for BOT/BAL and eventually its global footprint in oncology therapeutics. This agreement is an expression of confidence in the future of Agenus and in the regulatory environment of the United States. The administration has created an environment that has brought these two trading partners together.  The United States is the second largest trading partner with India. For these reasons and the strong collaborative spirit we feel with our new partners at Zydus, we decided to enter into this partnership now.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We are thrilled to be partnering with Agenus to advance BOT/BAL, which has the potential to benefit thousands of patients in our core markets of India and Sri Lanka annually and millions of solid tumor patients globally. We plan to run clinical trials testing BOT/BAL in both early-stage and late-stage disease, along with expansion beyond colorectal cancer to other major disease settings like triple negative breast cancer,&#x201d; said Dr. Sharvil Patel, Managing Director at Zydus Lifesciences Ltd.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The transaction is subject to customary closing conditions and satisfactory due diligence. The parties aim to complete closing agreements within 60 days.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Conference Call and Webcast</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Date/Time: Tuesday, June 3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">; 4:30 p.m. ET</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To access dial-in numbers, please register at: </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">https://registrations.events/direct/Q4I127881000000000</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Conference ID: 12788</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advisors</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As part of this effort, Agenus was advised by Biotech Value Advisors (BVA), a strategic advisory firm, which provided guidance on transaction structure, partner selection and negotiations.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About Agenus</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">www.agenusbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About Zydus Lifesciences</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27,000 people worldwide, including 1,400 scientists engaged in R&amp;D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About Botensilimab (BOT)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to &#x201c;cold&#x201d; tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus&#x2019; investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About Balstilimab (BAL)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PD-L2. It has been evaluated in &gt;900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words &#34;may,&#34; &#34;believes,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;hopes,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;forecasts,&#34; &#34;estimates,&#34; &#34;will,&#34; &#x201c;establish,&#x201d; &#x201c;potential,&#x201d; &#x201c;superiority,&#x201d; &#x201c;best in class,&#x201d; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agenus Investors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"><br>917-362-1370<br></font><font style="color:#467886;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">investor@agenusbio.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agenus Media</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"><br>781-674-4422</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#467886;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">communications@agenusbio.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Source: Agenus Inc.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img250783414_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img250783414_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ? )@# 2(  A$! Q$!_\0
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M?AYH-GJ<UA$(?"&C>+?"ESHM[JU[97]]IUC"L>BCP]/I&I6EB;V]FNQ^A?\
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M_=?]E*\$_P#H&LU5[37_ &[T2Z*^FJ1G_P N_P"N_P C[=_9P\;ZI\2?V?\
MX+>/=>NQ?Z_XL^%_@C6_$-\L4%NMYX@O?#NGR:[=)!;1PVT*7&K?;)4BMXHH
M(U<)%&D:JH_%K_@L+X U+X?K\/\ QOH/Q/\ BW<V/Q$\2>,+?7O NO?$;Q-K
MG@FPNK:UL-7M)_"F@W]S<6WAVT5KB]2\TFU;^S/L,-G:Z5:Z<EO+!>_K3^Q%
M_P FB_LZ_P#9*/"7_INCK\X/^"W8/_"N_@.<' \:>+P3C@$Z'IA )Z9(!P.^
M#Z&E'247YK\QOX/DOT/UNNO!MM\0_A)HWA:_U_QEX;CU3PSX8<Z]X#\6:UX+
M\66,]K:Z?>PSZ=XBT*ZM=0MV::!5NH'>6SU"V>:RU&UNK*XGMY/Q5_X)T66M
M^'?^"B/[3G@?5?&7BOQO#X(\'_%OPI9:]XOU>[UG6]1M?#OQF\":39WFK75Q
M-)&^I2V5O UR]O%:P27+WLT%K;0S+ G[K>!)HKCP1X-GA=989_"OAZ:*1&#)
M)%+I%F\;HPX971@RL."""*_";_@GAX@TKQ7_ ,%*_P!KKQ-H-Y#J.AZ]I/QP
MU;1M2MEQ;ZEI=_\ ';P9=6%ZC]9([BSEM[BV<@%K:XB8JI) 2VEZ?JAR^S_B
M7ZG] =?SY7?Q+T#]J?\ X*&?$?X)_M0>/==T#X+^#=:\9>"OAK\,+7Q9JW@K
MP;XH\8>$=>LO#VCV6OW>E7EA+=:CXGM&\1>(K+4)+[3=9N]7DTOPMI>LBPET
MWP_J/]!M?FM^V)_P36^&/[3NI:A\0O#NK3?#7XOW5LB76OV]J-4\,>*Y+6UC
MMK-?%6@-)"\5^D%M!90>)-&N+>_LX"TU[8:]Y,%JHK==.S71W6O_  P23:5M
M=4VNZ[#M'_8:L/@3^TI\$_BM^S<OB3P[\.4O?%6A_&;X<OX_UN\\.G2M0\#Z
M_9>'/$]M9>)M7O+[5([+7Y[47^BM?ZGY>HMH.KZ1IUE'IVJSN5^?/P,_:*_:
MJ_89_: \&?LR?M(WL_BSX<^(-6T+0M+N-5U.37H=(\/ZYJ4'AS1?&G@#Q9-;
M1ZM+X4TZ:$M>^&=4@$&GV.G7^FVFA^&M690Y0[WU=^M_ZU^\(V:=E;75=G9&
MI)^PA^VM^Q[^VUXZ_:5_8XT#X>_%WX?_ !3NO%[ZUX'\6^*K'PI>:5H?C77;
M?Q5J_A34#K%SIACM=,\10VEUX8UW0=7U&\V:3:'6M->.[U.ROK/[>'_!/;]M
MS]L[P'H7Q0\9^(_AH_QA\)ZG#9>#_P!G_P %ZO?67P^\)^ M5L[B7Q,;;QKX
MI%N-?^*.LZU#X9?6M1NH]"\-Q:7X?6WTN]O3:Z?#/_0A173'&5X5J>(C*U:E
MR\M2WO/E5ES='IIM=K1L_=<#](7Q R[BC@WCG!QX>H<;\%97EF18/BV&2TUG
M&;Y)E&#CE>"RW/\ ]]]0QK62Q618K-</@<'G^89*Y9;C\VQ.&E*#\#_9M?\
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C:7P\=.U;5S&VN7,$MM<2:7IUGH=GH5O,]QXGE*_7.B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>agen-20250603.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-06-04T16:35:28.1053+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.agenusbio.com/20250603" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:agen="http://www.agenusbio.com/20250603" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="agen-20250603.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 03, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  03,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AGENUS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001098972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-29089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1562417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3 Forbes Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lexington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">674-4400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="agen-20250603.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="agen-20250603.htm">agen-20250603.htm</File>
    <File>agen-20250603.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "agen-20250603.htm": {
   "nsprefix": "agen",
   "nsuri": "http://www.agenusbio.com/20250603",
   "dts": {
    "inline": {
     "local": [
      "agen-20250603.htm"
     ]
    },
    "schema": {
     "local": [
      "agen-20250603.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agen-20250603.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agen-20250603.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.agenusbio.com/20250603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0000950170-25-081674-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-081674-xbrl.zip
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M@5W=)0<?SHAA:ETH.)48> #6$W'9V0A<CAR;&UYHT,#$_>>FZ<.OR*+<-<W
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MUP8\9GL91-KT1<T"P'J)!1J+L<B'A(5HMDES:^IPF&)6.\=]><N=VO LP<)
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M"[0MT#8<:%;7?)#%HLI_,^!M6>06<;= VP)M"[3OZ=3^YQ%5*W.NW6ME#L&
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MI4OE+P-Q\N[T_89A[UE'2)$IF4*60-?I/*\*TS4%@30AL5.8&8<".K#+4KF
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M&3UUG5Z<A+1H3GDA7<!TR6,_*JP/,/>&>.SS^;PG>4$C;7K ZF8ZXP*8_%N
M\]\$J#A;8C0DOG.YH(Q?<S G\5*H(B8S,#;?@-) GP65^$(>4LK;A.S=7(VH
M_RSD"PR35:XH@4>=A'C_7BVZS]+$N9V1^SPP= \(^5AO>!#N!;=6DM#AZHE0
MI4G25H%4YR$Y72I#*5/^8&R52@VGHC(2NA R&?P?"O11UIC$R;C*QB'-36]
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M1<F__<O+'?X_QOXO4$L! A0#%     @ M83$6OT-&L*I&@  --,  !$
M         ( !     &%G96XM,C R-3 V,#,N:'1M4$L! A0#%     @ M83$
M6K%IN>5C"   5%T  !$              ( !V!H  &%G96XM,C R-3 V,#,N
M>'-D4$L! A0#%     @ M83$6C$EKC4N%   .'8   \              ( !
I:B,  &%G96XM97@Y.5\Q+FAT;5!+!08      P # +L   #%-P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>agen-20250603_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="agen-20250603.xsd" xlink:type="simple"/>
    <context id="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001098972</identifier>
        </entity>
        <period>
            <startDate>2025-06-03</startDate>
            <endDate>2025-06-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_e5edd971-83ab-4d37-89ff-dc7bb740703b">0001098972</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_a667d0ef-b20b-4a5e-9c17-f0e652e6c566">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_1174f8c9-889e-43e9-b0eb-6c58db1c99e3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_a52b9fe7-7637-4719-8eec-ba954e82bac4">2025-06-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_c025f7ba-9d03-42ec-8312-5e2c8e6d8d24">AGENUS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_2a65ade1-48ef-4335-906f-74de893392a8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_1a50f991-0774-4c01-984c-5693ca5e7c08">000-29089</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_ac175431-5d01-45f1-bfb6-327ba65f77f5">06-1562417</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_38fff53e-742a-4b97-8396-40f4365f5661">3 Forbes Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_843b8184-2c71-4985-851f-1c758ae7a0eb">Lexington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_21ee9edc-2d9c-4744-8ff9-15f65ddfa5e8">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_c67094a7-d5c3-40bc-94f9-733c2c5ac3c7">02421</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_7480dae3-a386-4bc0-9675-72236e702449">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_a1748922-0d7f-4c2b-ba9e-89c3e083d923">674-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_261ee0de-ca40-4458-8ee2-3683a48a4b77">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_d65e28c2-b337-4339-b3d4-e733b2259292">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_fa78a67b-c4fc-40ad-8657-8c8f3f7fe8e4">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_440c0d61-d3e1-4a18-9067-3bf89a55fb85">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_d0cd289a-6459-4b65-92ca-40cee4f6c120">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_f6fccacc-c20e-47e5-9333-2d044f384aa6">AGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_35aa30b9-6d1f-46e5-95bc-fe563123b61a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_d88b7fc1-8acc-4b17-ae86-ad11824ab9f8"
      id="F_6e47dc6d-9b19-4636-a3ca-213eade60afd">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
